What are the applicable targets of Seleniso (Sivio)?

Selinexor (Selinexor), as an innovative targeted therapy drug, has shown remarkable results in the field of anti-cancer. Its unique anti-cancer mechanism is mainly attributed to its precise attack on specific targets.

The central role of Seleniso (Silvio) is to target the nuclear transport protein XPO1. This protein plays a crucial role in the transport of proteins inside and outside cells, especially in regulating cell growth, death and the transmission of genetic information. Selinesol (Silvio) can effectively inhibit the activity of XPO1 and block its binding to proteins in the nucleus, thereby interfering with the living environment and proliferation ability of cancer cells.

In addition to For example, it activates the tumor suppressor p53, a gene that detects DNA damage and directs cells to self-destruct. By promoting the accumulation and activation of p53in the nucleus, Seleniso (Silvio)increases the sensitivity of cancer cells to DNA damage, thereby triggering their self-destruction.

Seleniso (Silvio) also affects nuclear factorκB (NF-κB), an important factor that controls cellular inflammatory responses, immune responses, and cell division. By regulating the NF-κB signaling pathway, Seleniso (Silvio) can inhibit the spread and growth of tumor cells, thereby achieving its anti-cancer effect.

It is worth mentioning that Seleniso (Silvio) can also increase the expression level ofp21, a cell cycle regulatory protein. p21It can control the cell division cycle and promote cell death. By upregulating p21, Selinesol (Silvio) further inhibits the growth and survival of tumor cells.

Seliniso (Silvio) By precisely targeting the nuclear transport protein XPO1 and other key targets such as p53, NF-κB and p21, a comprehensive attack on cancer cells is achieved. This multi-target regulatory strategy sets up obstacles in many aspects such as cell growth, death and genetic information transmission, making Seleniso (Silvio) of great application value in the treatment of malignant tumors.